Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on pediatric orthopedics, and its news flow reflects this specialization. Company announcements frequently cover revenue updates, financial guidance, and quarterly earnings, where OrthoPediatrics discusses performance across its trauma and deformity, scoliosis, and specialty bracing (OPSB) product lines, as well as metrics such as the number of children treated with its systems.
Readers following KIDS news can expect regular updates on financial results and outlook, including preliminary unaudited revenue releases, full quarterly earnings reports, and adjustments to annual guidance. These releases often highlight contributions from specific product categories, trends in domestic and international revenue, and management’s commentary on operational initiatives such as restructuring efforts and cost management.
OrthoPediatrics also issues news on product development and regulatory milestones. Recent examples include FDA approval of the 3P Pediatric Plating Platform Small-Mini System, additional FDA clearances within a single year, and EUMDR certification for spine, trauma, and deformity implants and instruments. The company reports on first clinical procedures with new systems, such as the VerteGlide Spinal Growth Guidance System for early onset scoliosis, and on portfolio expansions like new PediHip bracing products within OPSB.
In addition, KIDS news includes strategic and corporate updates, such as distribution partnerships (for example, with MY01 for Continuous Perfusion Sensing Technology), expansion of OPSB clinics and territories, participation in healthcare and investor conferences, and changes to the board of directors. Investors and observers who monitor this news stream gain insight into how OrthoPediatrics is evolving its pediatric orthopedic platform, broadening its product offering, and engaging with clinicians and the capital markets.
OrthoPediatrics (Nasdaq: KIDS) announced that partner iotaMotion received FDA 510(k) clearance to expand use of the iotaSOFT® cochlear implant insertion system to patients four years and older on Feb. 3, 2026. The clearance extends access to robotic-assisted cochlear implantation for school-aged children.
Cincinnati Children’s Hospital is the first dedicated pediatric center to adopt iotaSOFT, joining over 35 U.S. cochlear implant centers and many neurotology fellowship programs that have adopted the technology. OrthoPediatrics positions this as strategic growth for its Enabling Technologies division to expand beyond orthopedics while remaining capital-light.
OrthoPediatrics (Nasdaq: KIDS) reported preliminary unaudited full year 2025 net revenue of $236.1M, up 15% vs. 2024, with domestic revenue of $186.2M (+16%) and international revenue of $49.9M (+15%). Q4 2025 preliminary revenue was $61.3M (+16% YoY), with domestic Q4 at $48.4M (+13%) and international Q4 at $12.9M (+32%). The company generated approximately $6.0–$7.0M of Q4 free cash flow and reduced full-year free cash flow usage by over 50% vs. 2024. The company received EUMDR certification for Response Spine products and related trauma and deformity devices. For 2026, OrthoPediatrics guides revenue of $262M–$266M (11%–13% growth), expects ~$10M annual set deployment and projects $25M Adjusted EBITDA.
OrthoPediatrics (Nasdaq: KIDS) announced on November 13, 2025 an expansion of its OrthoPediatrics Specialty Bracing (OPSB) portfolio with two new product launches: the PediHip™ Rigid Brace and PediHip™ Modular Abduction System.
The PediHip products, developed with pediatric hip experts, are intended to treat developmental dysplasia of the hip (DDH) and provide post-operative stabilization for children age three years and younger. OrthoPediatrics now offers 31 systems within its OPSB division and positions the PediHip portfolio alongside its Trauma & Deformity products to address the pediatric hip care continuum.
OrthoPediatrics (Nasdaq: KIDS) will participate in three investor conferences in November–December 2025: a Stifel 2025 Healthcare Conference fireside chat on Nov 13, 2025 at 1:20 pm ET; a Jefferies Global Healthcare Conference presentation in London on Nov 18, 2025 at 12:00 pm ET; and a Piper 37th Annual Healthcare Conference fireside chat on Dec 4, 2025 at 9:30 am ET.
An audio webcast of the discussions will be available on the company investor relations website and a replay will be accessible for 90 days after each event.
OrthoPediatrics (NASDAQ: KIDS) reported third quarter 2025 results for the period ended September 30, 2025, with total revenue $61.2M (up 12% YoY) and adjusted EBITDA $6.2M (up 56% YoY).
U.S. revenue was $48.7M (14% increase) and international revenue was $12.5M (6% increase). Revenue excluding 7D capital sales was $60.7M (up 17% YoY). Trauma & Deformity revenue rose 17% to $44.1M; Scoliosis revenue rose 4% to $16.3M.
GAAP diluted loss per share was $0.50; non-GAAP diluted loss per share was $0.24. Free cash flow usage improved to $3.4M (Q3 2024: $11.6M). Cash and equivalents were $59.8M as of Sept 30, 2025. Company updated full-year 2025 revenue guidance to $233.5M–$234.5M and reiterated adjusted EBITDA target of $15M–$17M.
OrthoPediatrics (Nasdaq: KIDS) announced FDA approval of the 3P Pediatric Plating Platform Small-Mini System on October 28, 2025, the company’s 6th FDA approval in 2025. The system is a variable-angle locking plate-and-screw solution for pediatric trauma and deformity surgeries with procedure-specific and utility plates in 2.0mm, 2.4mm, 2.7mm, and 3.5mm sizes.
Features include specialized instruments, streamlined tray layouts, and color-coding to enhance operating room efficiency. The Small-Mini System follows the 3P Hip System and is slated for a limited market release in early 2026.
OrthoPediatrics (Nasdaq: KIDS) will release its third quarter 2025 financial results on October 28, 2025 after market close. The company will host a conference call on October 28, 2025 at 4:30 p.m. ET to discuss results.
Investors can access a live and archived webcast via the company website on the Investors page in the Events & Presentations section. The webcast replay will be available for at least 90 days after the event.
OrthoPediatrics (Nasdaq: KIDS) reported preliminary unaudited Q3 2025 net revenue of $61.2M, up 12% year-over-year, and helped over 37,100 children in the quarter, bringing lifetime patients to ~1.3M. Domestic revenue was ~$48.7M (+14%) and international ~$12.5M (+6%). Excluding 7D capital sales, Q3 revenue was ~$60.7M (+17%).
Full-year 2025 revenue guidance was revised to $233.5M–$234.5M (14%–15% growth), down from $237.0M–$242.0M, while adjusted EBITDA guidance of $15M–$17M and $15.0M set deployment expectation were reiterated. The company cited delayed 7D capital and Latin/South America orders as timing headwinds.
OrthoPediatrics (NASDAQ: KIDS) has successfully completed the first U.S. surgical procedures using its VerteGlide Spinal Growth Guidance System, a breakthrough treatment for Early Onset Scoliosis (EOS). The procedures were performed by Dr. Richard McCarthy and Dr. Kent Walker in Louisville, Kentucky.
The VerteGlide system, part of OrthoPediatrics' Scoliosis product suite, represents an innovative solution for complex spinal pathology in early onset scoliosis patients. The technology, which utilizes Shilla™ technology licensed from Medtronic, will be featured at the 60th Annual Meeting of the Scoliosis Research Society and the 19th International Congress on Early Onset Scoliosis later this year.
OrthoPediatrics (NASDAQ: KIDS) has announced a new distribution partnership with MY01 Inc. to expand access to MY01's Continuous Perfusion Sensing Technology (CPST) Platform for children and adolescents. The partnership focuses on addressing acute compartment syndrome, a time-sensitive emergency condition that particularly affects children with orthopedic traumatic injuries.
The collaboration combines MY01's innovative technology with OrthoPediatrics' dedicated pediatric sales force and medical education resources. This partnership aims to provide clinicians with better tools and training for diagnosing and treating compartment syndrome in pediatric patients, who often struggle to communicate symptoms effectively.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
